Evolving therapeutic landscape of advanced hepatocellular carcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Authors
Keywords
-
Journal
Nature Reviews Gastroenterology & Hepatology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-11-11
DOI
10.1038/s41575-022-00704-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
- (2022) Carla Montironi et al. GUT
- First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
- (2022) Yohann Loriot et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
- (2022) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile.
- (2022) Marco Sanduzzi Zamparelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial
- (2022) Jung Yong Hong et al. Genome Medicine
- Novel Cellular Therapies for Hepatocellular Carcinoma
- (2022) Harriet Roddy et al. Cancers
- Nivolumab Plus Relatlimab: First Approval
- (2022) Julia Paik DRUGS
- Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
- (2022) Masatoshi Kudo et al. EUROPEAN JOURNAL OF CANCER
- Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead
- (2022) Ian F. Tannock et al. JAMA Oncology
- Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
- (2022) Robin Kate Kelley et al. LANCET ONCOLOGY
- Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
- (2022) Andrew X. Zhu et al. NATURE MEDICINE
- Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study.
- (2021) Jessica Howell et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of tepotinib in hepatocellular carcinoma (HCC) with high-level MET amplification (METamp): Preclinical and clinical evidence.
- (2021) Sandrine J. Faivre et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells
- (2021) Simon J Dovedi et al. Cancer Discovery
- Hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Disease Primers
- Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
- (2021) Philippe Rochigneux et al. Cancers
- Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
- (2021) A. Vogel et al. ANNALS OF ONCOLOGY
- Thinking Differently about Cancer Treatment Regimens
- (2021) Jeff Settleman et al. Cancer Discovery
- Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
- (2021) Masatoshi Kudo Liver Cancer
- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
- (2021) D.J. McGrail et al. ANNALS OF ONCOLOGY
- Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
- (2021) Baek-Yeol Ryoo et al. BRITISH JOURNAL OF CANCER
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- Advances in immunotherapy for hepatocellular carcinoma
- (2021) Bruno Sangro et al. Nature Reviews Gastroenterology & Hepatology
- A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma
- (2021) Weiqin Yang et al. Science Translational Medicine
- Angiogenesis as a hallmark of solid tumors - clinical perspectives
- (2021) Jamal Majidpoor et al. CELLULAR ONCOLOGY
- CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities
- (2021) Maryam Akhoundi et al. CELLULAR ONCOLOGY
- Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
- (2021) Qijie Zhao et al. Frontiers in Immunology
- Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
- (2021) Masatoshi Kudo et al. Liver Cancer
- Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
- (2021) Shukui Qin et al. Lancet Gastroenterology & Hepatology
- Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
- (2021) Richard S. Finn et al. CLINICAL CANCER RESEARCH
- Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)
- (2021) Philipp K. Haber et al. GASTROENTEROLOGY
- Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC
- (2021) Chenhe Yi et al. HEPATOLOGY
- Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome
- (2021) Sally Temraz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma.
- (2021) Li Bai et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.
- (2021) Philipp K. Haber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
- (2021) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
- (2021) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
- (2021) Xiaoxiang Zhou et al. LANCET ONCOLOGY
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
- (2021) Zhenggang Ren et al. LANCET ONCOLOGY
- EGFR activation limits the response of liver cancer to lenvatinib
- (2021) Haojie Jin et al. NATURE
- Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
- (2021) Atsushi Hiraoka et al. Scientific Reports
- Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
- (2021) Gang Liu et al. Frontiers in Immunology
- Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling
- (2021) Robin K. Kelley et al. Liver Cancer
- Exploring the Interplay of Telomerase Reverse Transcriptase and β-Catenin in Hepatocellular Carcinoma
- (2021) Srishti Kotiyal et al. Cancers
- Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)
- (2021) Chun Han et al. Frontiers in Oncology
- 120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
- (2021) J.C-H. Yang et al. ANNALS OF ONCOLOGY
- Combination strategies to maximize the benefits of cancer immunotherapy
- (2021) Shaoming Zhu et al. Journal of Hematology & Oncology
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
- (2021) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
- (2021) Thomas Yau et al. LANCET ONCOLOGY
- Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
- (2021) Lukas Kraehenbuehl et al. Nature Reviews Clinical Oncology
- Immunotherapies for hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Oncolytic virotherapy as immunotherapy
- (2021) Alan Melcher et al. SCIENCE
- Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response
- (2021) Yu-Ting Yen et al. Nature Communications
- Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
- (2021) Zhuoyan Liu et al. Frontiers in Immunology
- First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials
- (2021) Giuseppe Cabibbo et al. Liver Cancer
- Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
- (2021) Jinzhu Mao et al. Journal for ImmunoTherapy of Cancer
- Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
- (2021) Shaoming Zhu et al. Journal for ImmunoTherapy of Cancer
- Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer
- (2021) Aditi Gupta et al. Communications Biology
- Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
- (2021) Tetsu Tomonari et al. JGH Open
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
- (2021) Maria Reig et al. JOURNAL OF HEPATOLOGY
- A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
- (2020) Xiaoyu Li et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex
- (2020) Youn-Sang Jung et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Molecular therapies for HCC: Looking outside the box
- (2020) Sandrine Faivre et al. JOURNAL OF HEPATOLOGY
- Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
- (2020) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
- (2020) Shukui Qin et al. LANCET ONCOLOGY
- The Emerging Role of the c-MET-HGF Axis in Non-small Lung Cancer Tumor Immunology and Immunotherapy
- (2020) Helen F. Titmarsh et al. Frontiers in Oncology
- The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
- (2020) Haiyu Wang et al. Frontiers in Cell and Developmental Biology
- Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression
- (2020) Yanan Liu et al. Frontiers in Cell and Developmental Biology
- A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma
- (2020) Lin Yu et al. CANCER BIOLOGY & THERAPY
- Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma
- (2020) Linsong Tang et al. CANCER LETTERS
- Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials
- (2020) Donghua Shi et al. CLINICAL CANCER RESEARCH
- Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference
- (2020) Josep M. Llovet et al. HEPATOLOGY
- Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC).
- (2020) Chih-Hung Hsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
- (2020) Ahmet Acar et al. Nature Communications
- Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
- (2020) Robert Vander Velde et al. Nature Communications
- Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
- (2020) Robin Park et al. Frontiers in Oncology
- ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma
- (2020) Ji Feng et al. ACTA PHARMACOLOGICA SINICA
- Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
- (2020) Robin Kate Kelley et al. CLINICAL CANCER RESEARCH
- Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
- (2020) Matthias Pinter et al. GUT
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
- (2020) Michael S Lee et al. LANCET ONCOLOGY
- Rational Cancer Treatment Combinations: An Urgent Clinical Need
- (2020) Julia Boshuizen et al. MOLECULAR CELL
- TGFβ biology in cancer progression and immunotherapy
- (2020) Rik Derynck et al. Nature Reviews Clinical Oncology
- The Contribution of Epigenetics to Cancer Immunotherapy
- (2020) Lorea Villanueva et al. TRENDS IN IMMUNOLOGY
- Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
- (2020) João M. Fernandes Neto et al. Nature Communications
- Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
- (2020) Masami Yamauchi et al. Clinical and Translational Gastroenterology
- Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
- (2020) Jayesh Desai et al. Journal for ImmunoTherapy of Cancer
- Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a non-randomized, open-label, phase 2 trial
- (2020) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
- (2020) Yung-Jue Bang et al. EUROPEAN JOURNAL OF CANCER
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
- (2020) Tomoko Aoki et al. Cancers
- Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
- (2020) Shuo Chen et al. CANCER CELL
- Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma
- (2020) Yunfan Sun et al. CELL
- ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma
- (2020) Yuta Myojin et al. CLINICAL CANCER RESEARCH
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
- (2020) John D. Gordan et al. JOURNAL OF CLINICAL ONCOLOGY
- Adoptive cell therapy: Living drugs against cancer
- (2020) Tamara Laskowski et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting the Wnt/β-catenin signaling pathway in cancer
- (2020) Ya Zhang et al. Journal of Hematology & Oncology
- Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target
- (2020) Massih Ningarhari et al. JOURNAL OF HEPATOLOGY
- Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
- (2020) Daniel Q. Huang et al. Nature Reviews Gastroenterology & Hepatology
- Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
- (2020) Giuseppe Cabibbo et al. Cancers
- Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma
- (2019) Young K. Hong et al. CELLULAR IMMUNOLOGY
- Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC
- (2019) Roser Pinyol et al. CLINICAL CANCER RESEARCH
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
- (2019) Yongshuai Jiang et al. Human Vaccines & Immunotherapeutics
- Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
- (2019) Michael Teufel et al. GASTROENTEROLOGY
- The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma
- (2019) David Agdashian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study
- (2019) David J. Pinato et al. BRITISH JOURNAL OF CANCER
- RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
- (2019) Shukui Qin et al. Future Oncology
- Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor Galunisertib ( LY 2157299) in Advanced Hepatocellular Carcinoma
- (2019) Sandrine Faivre et al. LIVER INTERNATIONAL
- From NASH to HCC: current concepts and future challenges
- (2019) Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
- (2019) Lihu Gu et al. BMC CANCER
- Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
- (2019) Lynn G. Feun et al. CANCER
- Capecitabine in advanced hepatocellular carcinoma: A multicenter experience
- (2019) Filippo Pelizzaro et al. DIGESTIVE AND LIVER DISEASE
- Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
- (2019) Josep M. Llovet et al. JOURNAL OF HEPATOLOGY
- Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis
- (2019) Jisun Park et al. Targeted Oncology
- Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma
- (2019) Jian Chen et al. TRENDS IN MOLECULAR MEDICINE
- β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
- (2019) Marina Ruiz de Galarreta et al. Cancer Discovery
- Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
- (2019) Yi Zheng et al. Journal for ImmunoTherapy of Cancer
- Dual PD ‐1 and VEGFR ‐2 blockade promotes vascular normalization and enhances anti‐tumor immune responses in HCC
- (2019) Kohei Shigeta et al. HEPATOLOGY
- The emerging role of epigenetic therapeutics in immuno-oncology
- (2019) Michael J. Topper et al. Nature Reviews Clinical Oncology
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- (2019) Scott Kopetz et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma
- (2019) Richard D Kim et al. Cancer Discovery
- Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
- (2019) Qiang Gao et al. CELL
- Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
- (2019) Qiming Zhang et al. CELL
- Inducing and exploiting vulnerabilities for the treatment of liver cancer
- (2019) Cun Wang et al. NATURE
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
- (2019) Jianchun Duan et al. JAMA Oncology
- An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
- (2018) Liqin Wang et al. CELL
- Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients withRAS-mutated Hepatocellular Carcinoma
- (2018) Ho Yeong Lim et al. CLINICAL CANCER RESEARCH
- MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer
- (2018) Maria Saigi et al. CLINICAL CANCER RESEARCH
- Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway
- (2018) Jian Chen et al. GASTROENTEROLOGY
- Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
- (2018) Mohamed Bouattour et al. HEPATOLOGY
- Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
- (2018) Shetal A. Patel et al. IMMUNITY
- Characterization of Multiple Cytokine Combinations and TGF-β on Differentiation and Functions of Myeloid-Derived Suppressor Cells
- (2018) Cho-Rong Lee et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dendritic Cell–Based Cancer Vaccines
- (2018) Patricia M. Santos et al. JOURNAL OF IMMUNOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma
- (2018) Melanie B. Thomas et al. ONCOLOGY
- Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
- (2018) Chi Ma et al. SCIENCE
- PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
- (2018) Jake S. O’Donnell et al. SEMINARS IN CANCER BIOLOGY
- Harnessing Tumor Evolution to Circumvent Resistance
- (2018) Katherine L. Pogrebniak et al. TRENDS IN GENETICS
- Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer
- (2018) Maher Albitar et al. Oncotarget
- Taking advantage of drug resistance, a new approach in the war on cancer
- (2018) Liqin Wang et al. Frontiers of Medicine
- Characterization of Hepatocellular Carcinoma Patients with FGF19 Amplification Assessed by Fluorescence in situ Hybridization: A Large Cohort Study
- (2018) Hyo Jeong Kang et al. Liver Cancer
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model
- (2018) Diana Llopiz et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
- (2018) Takayuki Kimura et al. CANCER SCIENCE
- Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
- (2018) James J Harding et al. CLINICAL CANCER RESEARCH
- Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
- (2018) Yu-Yang Lin et al. SEMINARS IN LIVER DISEASE
- Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein−Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma
- (2017) Hidetoshi Nakagawa et al. GASTROENTEROLOGY
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy
- (2017) Nicole Glodde et al. IMMUNITY
- Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
- (2017) Richard Jackson et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Cutting Edge: Chromatin Accessibility Programs CD8 T Cell Memory
- (2017) Christopher D. Scharer et al. JOURNAL OF IMMUNOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Synthetic lethality and cancer
- (2017) Nigel J. O'Neil et al. NATURE REVIEWS GENETICS
- High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer
- (2017) Liqin Wang et al. Cell Reports
- The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level
- (2017) et al. JAMA Oncology
- A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
- (2016) T. Ciuleanu et al. ANNALS OF ONCOLOGY
- Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
- (2016) D. Koeberle et al. ANNALS OF ONCOLOGY
- The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway
- (2016) DONGDONG WANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
- (2016) Chi Ma et al. NATURE
- A combinatorial strategy for treating KRAS-mutant lung cancer
- (2016) Eusebio Manchado et al. NATURE
- A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer
- (2016) Daniel Dauch et al. NATURE MEDICINE
- Combine and conquer: challenges for targeted therapy combinations in early phase trials
- (2016) Juanita S. Lopez et al. Nature Reviews Clinical Oncology
- Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
- (2016) K. E. Pauken et al. SCIENCE
- Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment
- (2016) Valery Vilchez WORLD JOURNAL OF GASTROENTEROLOGY
- Histone Modifications and Cancer
- (2016) James E. Audia et al. Cold Spring Harbor Perspectives in Biology
- TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype
- (2016) Fan Zhang et al. Oncotarget
- Tumor-Suppressor Functions of the TP53 Pathway
- (2016) Brandon J. Aubrey et al. Cold Spring Harbor Perspectives in Medicine
- Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma
- (2016) Min He et al. OncoImmunology
- Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
- (2016) Yu Sawada et al. OncoImmunology
- Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response
- (2015) Winnie Yeo et al. BMC CANCER
- Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma
- (2015) Eishiro Mizukoshi et al. CANCER LETTERS
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
- (2015) Jessica Zucman-Rossi et al. GASTROENTEROLOGY
- EGFR Signaling in Liver Diseases
- (2015) Karin Komposch et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study
- (2015) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib
- (2015) Yu Yang et al. LIVER INTERNATIONAL
- Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
- (2015) Joong-Won Park et al. LIVER INTERNATIONAL
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma
- (2015) Shan-Shan Jiang et al. Oncotarget
- Therapeutic targeting of tumor suppressor genes
- (2014) Luc G. T. Morris et al. CANCER
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
- (2014) Susann Weissmueller et al. CELL
- Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis
- (2014) Jean Charles Nault et al. HEPATOLOGY
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- TGF- Inhibits IL-2 Production and Promotes Cell Cycle Arrest in TCR-Activated Effector/Memory T Cells in the Presence of Sustained TCR Signal Transduction
- (2014) L. Das et al. JOURNAL OF IMMUNOLOGY
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
- (2014) E. Horwitz et al. Cancer Discovery
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
- (2013) L. Goyal et al. CLINICAL CANCER RESEARCH
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Met as a therapeutic target in HCC: Facts and hopes
- (2013) Silvia Giordano et al. JOURNAL OF HEPATOLOGY
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- PTEN functions as a melanoma tumor suppressor by promoting host immune response
- (2013) Y Dong et al. ONCOGENE
- Neuropilin 1 deficiency on CD4+Foxp3+regulatory T cells impairs mouse melanoma growth
- (2012) Wiebke Hansen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
- (2011) Qian Zhou et al. Future Oncology
- PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB–Cytokine Network
- (2011) Haoqiang Ying et al. Cancer Discovery
- The Liver as a Lymphoid Organ
- (2009) Ian Nicholas Crispe Annual Review of Immunology
- FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation
- (2009) Xinle Wu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- EpCAM and -Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
- (2008) T. Yamashita et al. CANCER RESEARCH
- Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
- (2008) Augusto Villanueva et al. GASTROENTEROLOGY
- A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma
- (2008) Daniel H. Palmer et al. HEPATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
- (2008) S. Shangary et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started